Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses.

Area of Science:

• Oncology
• Therapeutic Modalities
• Cancer Treatment

Background:

• Moderate hyperthermia (40-44°C) is a versatile cancer therapy.
• It acts as a radiosensitizer and enhances chemotherapy efficacy.
• Hyperthermia combined with radiotherapy induces tumor-specific immunomodulation.

Purpose of the Study:

• To analyze the strengths, weaknesses, opportunities, and threats (SWOT) of hyperthermia in oncology.
• To categorize future strategies for integrating hyperthermia with existing treatments (TOWS analysis).
• To highlight hyperthermia's potential as a safe, versatile, and cost-effective therapeutic enhancement.

Main Methods:

• Review of existing clinical trials, systematic reviews, and meta-analyses on hyperthermia.
• Analysis of technological advancements in hyperthermia delivery and planning.
• SWOT and TOWS analysis to assess hyperthermia's strategic position and future integration.

Main Results:

• Hyperthermia, combined with radiotherapy and/or chemotherapy, improves outcomes without increasing toxicity.
• Technological advancements ensure safe and effective hyperthermia delivery.
• Novel biological modeling and nanoparticle-based delivery offer new theranostic possibilities.

Conclusions:

• Hyperthermia is a powerful radiosensitizer and potentiator of chemotherapy and immunotherapy.
• Advancements in technology and planning facilitate safe and effective hyperthermia delivery.
• Strategic integration of hyperthermia offers significant potential to enhance cancer treatment outcomes.